Brainstorm Cell proposes governance reforms to settle NurOwn derivative suits, with $725,000 in fees
The ALS cell therapy developer, as nominal defendant, has signed a stipulation to resolve stockholder suits over statements on FDA concerns about NurOwn; the deal needs court approval.
Brainstorm Cell Therapeutics has signed a stipulation, dated 2 November 2026, to settle a group of stockholder derivative proceedings tied to its NurOwn programme for amyotrophic lateral sclerosis (ALS). The company is a nominal defendant in the cases, meaning any claims are brought on its behalf against current and former officers and directors.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Company's press release (SEC filing): Brainstorm Cell Therapeutics Inc. ↗
Article written by VigiEye from the official source (Brainstorm Cell Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.